SOUTH
SAN FRANCISCO, Calif., Dec. 2, 2024
/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a
precision medicine oncology company committed to the discovery and
development of targeted therapeutics, announced its participation
in upcoming investor relations events.
Citi's 2024 Global Healthcare Conference
Tuesday, December 3rd, 2024 at
8:00 AM ET
- Fireside chat with Yujiro S.
Hata, President and Chief Executive Officer, hosted by
Yigal D. Nochomovitz, Ph.D.,
Director, SMid Cap Biotech Analyst
7th Annual Evercore HealthCONx Conference
Wednesday, December 4th, 2024 at
1:20 PM ET
- Fireside chat with Yujiro S.
Hata, President and Chief Executive Officer, hosted by
Jonathan Miller, Managing Director,
Biotech and Pharma Equity Research
A live audio webcast of the conference event, as permitted by
the conference host, will be available at the "Investors/Events"
section of the IDEAYA website at https://ir.ideayabio.com/events
and/or through the conference host. A replay of the webcast will be
accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's approach
integrates capabilities in identifying and validating translational
biomarkers with drug discovery to select patient populations most
likely to benefit from its targeted therapies. IDEAYA is applying
its early research and drug discovery capabilities to synthetic
lethality – which represents an emerging class of precision
medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to participation
in and/or presentation at certain investor relations events. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's current
and future filings with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 10-K filed on
February 20, 2024.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-participation-in-upcoming-december-2024-investor-relations-events-302319106.html
SOURCE IDEAYA Biosciences, Inc.
